24th November 2017
Runtime 04:53
Cameron Reynolds, Volition CEO, told London South East he expects to hit significant clinical test milestones in 2018 and to get a CE Mark and to begin selling their colorectal cancer blood test in Europe in Q3 2018.
As yet there is no blood test for cancer (apart from prostate), which means there is great support from clinicians, doctors, institutions and governments in Volition's unique simple blood test. Volition is NYSE-listed: VNRX and currently has a market cap of just under 100M$.
The Volition interview is one of a series of interviews with Edison pharma clients shot at the Biotech and Money Conference 2017 at the Waldorf Hotel, London, on 14.11.2017.
